AU2021227095B2 - Daptomycin formulation - Google Patents

Daptomycin formulation Download PDF

Info

Publication number
AU2021227095B2
AU2021227095B2 AU2021227095A AU2021227095A AU2021227095B2 AU 2021227095 B2 AU2021227095 B2 AU 2021227095B2 AU 2021227095 A AU2021227095 A AU 2021227095A AU 2021227095 A AU2021227095 A AU 2021227095A AU 2021227095 B2 AU2021227095 B2 AU 2021227095B2
Authority
AU
Australia
Prior art keywords
daptomycin
formulation
reconstitution time
solid
solid formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2021227095A
Other languages
English (en)
Other versions
AU2021227095A1 (en
Inventor
Barbara FUMIC
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xellia Pharmaceuticals ApS
Original Assignee
Xellia Pharmaceuticals ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xellia Pharmaceuticals ApS filed Critical Xellia Pharmaceuticals ApS
Publication of AU2021227095A1 publication Critical patent/AU2021227095A1/en
Application granted granted Critical
Publication of AU2021227095B2 publication Critical patent/AU2021227095B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2021227095A 2020-02-28 2021-02-26 Daptomycin formulation Active AU2021227095B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062982945P 2020-02-28 2020-02-28
US62/982,945 2020-02-28
PCT/EP2021/054841 WO2021170807A1 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Publications (2)

Publication Number Publication Date
AU2021227095A1 AU2021227095A1 (en) 2022-08-25
AU2021227095B2 true AU2021227095B2 (en) 2024-02-22

Family

ID=74797935

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021227095A Active AU2021227095B2 (en) 2020-02-28 2021-02-26 Daptomycin formulation

Country Status (9)

Country Link
US (1) US12629337B2 (cg-RX-API-DMAC7.html)
EP (1) EP4110303A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516957A (cg-RX-API-DMAC7.html)
CN (2) CN118873500A (cg-RX-API-DMAC7.html)
AU (1) AU2021227095B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022015571A2 (cg-RX-API-DMAC7.html)
MX (1) MX2022010378A (cg-RX-API-DMAC7.html)
WO (1) WO2021170807A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202208343B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759497B2 (en) 2017-08-31 2023-09-19 Xellia Pharmaceuticals Aps Daptomycin formulations
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation
WO2026111848A1 (en) * 2024-11-21 2026-05-28 MAIA Pharmaceuticals, Inc. Daptomycin compositions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043008A1 (en) * 2017-08-31 2019-03-07 Xellia Pharmaceuticals Aps DAPTOMYCIN FORMULATIONS

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4885243A (en) 1984-10-09 1989-12-05 Eli Lilly And Company Process for producing A-21978C derivatives
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU2001267011B2 (en) 2000-06-21 2006-02-02 Cubist Pharmaceuticals, Inc. Compositions and methods to improve the oral absorption of antimicrobial agents
JP2003055256A (ja) * 2001-08-10 2003-02-26 Nihon Pharmaceutical Co Ltd 安定な血液凝固第xiii因子製剤
CA2781666C (en) 2009-11-23 2017-02-21 Cubist Pharmaceuticals, Inc. Lipopeptide compositions and related methods
US20110124551A1 (en) 2009-11-23 2011-05-26 Eagle Pharmaceuticals, Inc. Formulations of daptomycin
WO2013103801A1 (en) 2012-01-04 2013-07-11 Hospira, Inc. Pharmaceutical spray drying
NO2887953T3 (cg-RX-API-DMAC7.html) 2012-08-23 2018-03-10
PL4066849T3 (pl) 2012-09-11 2025-06-16 Hospira Australia Pty Ltd Preparaty daptomycyny i ich zastosowania
WO2016098009A1 (en) 2014-12-16 2016-06-23 Dr. Reddy’S Laboratories Limited Lyophilized injectable compositions of daptomycin
CN106943587B (zh) 2016-01-06 2021-06-22 山东新时代药业有限公司 一种注射用达托霉素冻干粉针及其制备工艺
GB201718888D0 (en) * 2017-11-15 2017-12-27 Ucb Biopharma Sprl Method
EP4110303A1 (en) 2020-02-28 2023-01-04 Xellia Pharmaceuticals ApS Daptomycin formulation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019043008A1 (en) * 2017-08-31 2019-03-07 Xellia Pharmaceuticals Aps DAPTOMYCIN FORMULATIONS

Also Published As

Publication number Publication date
JP2025142200A (ja) 2025-09-30
US20230068866A1 (en) 2023-03-02
BR112022015571A2 (pt) 2022-09-27
AU2021227095A1 (en) 2022-08-25
EP4110303A1 (en) 2023-01-04
MX2022010378A (es) 2022-09-21
CN118873500A (zh) 2024-11-01
WO2021170807A1 (en) 2021-09-02
CN115038431B (zh) 2024-08-09
US12629337B2 (en) 2026-05-19
JP2023516957A (ja) 2023-04-21
CA3168727A1 (en) 2021-09-02
CN115038431A (zh) 2022-09-09
ZA202208343B (en) 2024-11-27

Similar Documents

Publication Publication Date Title
US12053502B2 (en) Daptomycin formulations
JP6239167B2 (ja) リポペプチド組成物および関連する方法
US12629337B2 (en) Daptomycin formulation
KR20040085196A (ko) 항신생물제, 특히 테모졸로마이드의 약제학적 제형, 이의제조 및 사용 방법
JP2013511522A (ja) ダプトマイシン製剤
CN113811290A (zh) 达托霉素水性制剂
WO2017085696A1 (en) Parenteral formulations of melphalan
JP2025533237A (ja) 液体ダルババンシン組成物
KR20230146515A (ko) 개선된 동결건조 제형
US20260137753A1 (en) Daptomycin compositions
WO2023209731A1 (en) Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation
WO2005123137A2 (en) Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)